Key Points It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock. 10 stocks we like better than Xeris Biopharma › A competitor's setback was Xeris Biopharma's (NASDAQ: XERS) gain on Hump Day. On news that a potential commercial threat to one of its three commercialized drugs had been neutralized (at least for now), investors piled into Xeris stock, sending it to a more than 7% price gain. A bullish analyst note reinforced this positive sen ...